Company Overview and News

 
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y

3h zacks
Dr. Reddy's Laboratories Ltd. (RDY - Free Report) reported fourth-quarter fiscal 2018 earnings per American Depositary Share (ADS) of 28 cents, down 3.5% from 29 cents earned in the year-ago quarter.

 
Allergan Stock Down Since Q1 Earnings Report: Here's Why

7h zacks
Shares of Allergan plc (AGN - Free Report) have declined 4.4% since it reported its first-quarter 2018 results on Apr 30. In fact, so far this year, Allergan’s share price has declined 5.3%, compared with the industry’s decline of 6.8%.

 
Tiny but mighty, small US companies are beating bigger rivals

2018-05-22 money.cnn
The Russell 2000 (RUT), an index that includes shares of mostly smaller US companies, is up nearly 7% this year and is trading at an all-time high.

 
Inovio Initiates Phase II Study on Pipeline Drug VGX-3100

2018-05-22 zacks
Inovio Pharmaceuticals, (INO - Free Report) has initiated a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia. This will be the third indication that VGX-3100 will be evaluated for. It is already being evaluated to treat HPV-related vulvar and anal precancers.

 
Lear (LEA) Hits Fresh Highs: Is There Still Room to Run?

2018-05-22 zacks
Have you been paying attention to shares of Lear (LEA - Free Report) ? Shares have been on the move with the stock up 5.7% over the past month. LEA hit a new 52-week high of $204.99 in the previous session. Lear has gained 14.9% since the start of the year compared to the -0.2% move for the Auto-Tires-Trucks sector and the 5.7% year-to-date return for its peer group.

 
Blucora (BCOR) Hits Fresh Highs: Is There Still Room to Run?

2018-05-22 zacks
Have you been paying attention to shares of Blucora (BCOR - Free Report) ? Shares have been on the move with the stock up 41.8% over the past month. BCOR hit a new 52-week high of $37.35 in the previous session. Blucora has gained 68.1% since the start of the year compared to the 9.6% move for the Business Services sector and the 18.4% year-to-date return for its peer group.

 
Guess? (GES) Hits a 52-Week High, Can the Run Continue?

2018-05-22 zacks
Have you been paying attention to shares of Guess? (GES - Free Report) ? Shares have been on the move with the stock up 13.8% over the past month. GES hit a new 52-week high of $26.15 in the previous session. Guess? has gained 53.1% since the start of the year compared to the 2.3% move for the Consumer Discretionary sector and the 14% year-to-date return for its peer group.

 
AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia

2018-05-21 zacks
AstraZeneca (AZN - Free Report) announced that the FDA has approved Lokelma (sodium zirconium cyclosilicate) formerly known as ZS-9, for the treatment of hyperkalemia in adults. Hyperkalemia is a serious condition characterized by high levels of potassium in the blood and Lokelma is a highly selective, oral potassium-removing agent.

 
Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?

2018-05-21 zacks
Have you been paying attention to shares of Ligand Pharmaceuticals (LGND - Free Report) ? Shares have been on the move with the stock up 15.7% over the past month. LGND hit a new 52-week high of $195.17 in the previous session. Ligand Pharmaceuticals has gained 42.4% since the start of the year compared to the -0.4% move for the Medical sector and the -6.5% year-to-date return for its peer group.

 
Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study

2018-05-18 zacks
Pfizer Inc. (PFE - Free Report) announced that a phase III study evaluating its epilepsy drugLyrica (pregabalin) in pediatric patients met the primary endpoint. The study was evaluating the use of Lyrica Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age, an indication for which Lyrica is not yet approved.

 
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down

2018-05-18 zacks
AstraZeneca plc (AZN - Free Report) missed the Zacks Consensus Estimate for both earnings and sales in the first quarter of 2018 hit by declining sales of its cholesterol drug, Crestor. The Swiss pharma giant maintained its previously issued outlook for 2018. The stock declined more than 2% in pre-market trading on Friday.

 
Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data

2018-05-17 zacks
Biotech major Amgen Inc. (AMGN - Free Report) gained approval from the European Commission (EC) for its regulatory application seeking approval to include data from the cardiovascular outcomes study, FOURIER, on the European label of its PCSK9 inhibitor, Repatha.

 
Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion

2018-05-17 zacks
Zoetis Inc. (ZTS - Free Report) announced a definitive deal to acquire Caifornia-based Abaxis Inc. (ABAX - Free Report) , a leading global provider of veterinary point-of-care diagnostic instruments, for $83 per share in cash or a total of $2 billion.

 
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

2018-05-16 zacks
Sanofi (SNY - Free Report) and partner Regeneron Pharmaceuticals (REGN - Free Report) announced that a phase III study evaluating its atopic dermatitis (eczema) drug Dupixent (dupilumab) in adolescent patients (aged 12-17) met its primary and key secondary endpoints.

 
Roche's Actemra Gets FDA Nod for Subcutaneous Formulation

2018-05-15 zacks
Roche Holding AG’s (RHHBY - Free Report) subsidiary Genentech announced that the FDA has approvedan alternative delivery option for itsrheumatoid arthritis drug Actemra. Asubcutaneous (SC) formulation of Actemra (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) for patients two years or older has been approved by the FDA.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 53220K173